Compare TRNO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRNO | TGTX |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.0B |
| IPO Year | 2009 | 2008 |
| Metric | TRNO | TGTX |
|---|---|---|
| Price | $64.33 | $40.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $67.83 | $49.80 |
| AVG Volume (30 Days) | 651.8K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | 103.65 | ★ 1746.67 |
| EPS | ★ 0.66 | 0.12 |
| Revenue | ★ $476,383,000.00 | $2,785,000.00 |
| Revenue This Year | $8.42 | $49.08 |
| Revenue Next Year | $9.10 | $26.69 |
| P/E Ratio | ★ $97.73 | $338.00 |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $53.00 | $25.37 |
| 52 Week High | $67.55 | $44.65 |
| Indicator | TRNO | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 58.67 |
| Support Level | $64.01 | $38.20 |
| Resistance Level | $67.05 | $44.65 |
| Average True Range (ATR) | 1.19 | 1.42 |
| MACD | -0.25 | -0.14 |
| Stochastic Oscillator | 35.66 | 67.69 |
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.